Effect of controlled zinc release on bone mineral density from injectable Zn-containing beta-tricalcium phosphate suspension in zinc-deficient diseased rats.

The purpose of this study was to evaluate the efficacy of zinc (Zn)-containing beta-tricalcium phosphate (Zn-TCP) in correcting the bone mineral deficiency noted in osteoporosis using ovariectomized rat model. Four rats were used for each of the four experimental groups: D0, D10, D20, and N10. The rats in D0, D10, and D20 groups were ovariectomized, and fed a vitamin D-, Ca-, and Zn-deficient diet, and induced Zn-deficient osteoporoses for 9 weeks.

Effect of particle size on zinc release from zinc containing tricalcium phosphate (ZnTCP) in Zn-deficient osteoporosis rats.

The effect of particle size on in vivo and in vitro Zn release of ZnTCP was investigated for the purpose of understanding Zn release behavior from a sustained-release device. The tricalcium phosphate powders (Ca2.7 Zn0.

Calcium level-responsive in-vitro zinc release from zinc containing tricalcium phosphate (ZnTCP).

The in vitro Zn release from tricalcium phosphate containing Zn (ZnTCP; 0.63, 6.17, and 12.

[General anesthesia with sevoflurane and vecuronium for patients with dystrophia myotonica and progressive muscular dystrophy].

A 9 year old male previously diagnosed as progressive muscular dystrophy whose serum CPK5430IU.l-1 was very high received general anesthesia. Before anesthesia, dantrolene sodium 2 mg.

[Anesthetic management of revascularization for moyamoya disease].

Anesthetic management during 85 STA-MCA anastomoses with or without encephalo-myosynangiosis for 64 patients with Moyamoya disease was evaluated retrospectively. Anesthetic agents included nitrous oxide-NLA (GONLA), nitrous oxide-halothane (GOF), nitrous oxide-enflurane (GOE), and their combinations. Slight hypercarbia (40 mmHg less than PaCO2 less than 50 mmHg) was essential to avoid cerebral ischemia.